Potentially valid drugs are sometimes denied FDA approval because flawed clinical data undermines efficacy and safety findings, says Health Decisions. The company notes that risk is at an all-time high in clinical development. In a new white paper, the group describes factors that make some trials riskier than others, as well as systematic risk mitigation. Release